SMT201300007B - Trattamento di una malattia respiratoria - Google Patents

Trattamento di una malattia respiratoria

Info

Publication number
SMT201300007B
SMT201300007B SM201300007T SM201300007T SMT201300007B SM T201300007 B SMT201300007 B SM T201300007B SM 201300007 T SM201300007 T SM 201300007T SM 201300007 T SM201300007 T SM 201300007T SM T201300007 B SMT201300007 B SM T201300007B
Authority
SM
San Marino
Prior art keywords
treatment
respiratory disease
respiratory
disease
Prior art date
Application number
SM201300007T
Other languages
English (en)
Inventor
Harry Finch
Craig Fox
Mohammed Sajad
Original Assignee
Pulmagen Therapeutics Inflammation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0814488A external-priority patent/GB0814488D0/en
Priority claimed from GB0823568A external-priority patent/GB0823568D0/en
Application filed by Pulmagen Therapeutics Inflammation Ltd filed Critical Pulmagen Therapeutics Inflammation Ltd
Publication of SMT201300007B publication Critical patent/SMT201300007B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM201300007T 2008-08-07 2013-01-17 Trattamento di una malattia respiratoria SMT201300007B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0814488A GB0814488D0 (en) 2008-08-07 2008-08-07 Respiratory disease treatment
GB0823568A GB0823568D0 (en) 2008-12-24 2008-12-24 Respiratory disease treatment
PCT/GB2009/001920 WO2010015818A1 (en) 2008-08-07 2009-08-05 Respiratory disease treatment

Publications (1)

Publication Number Publication Date
SMT201300007B true SMT201300007B (it) 2013-03-08

Family

ID=41202662

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300007T SMT201300007B (it) 2008-08-07 2013-01-17 Trattamento di una malattia respiratoria

Country Status (21)

Country Link
EP (1) EP2222272B1 (it)
JP (1) JP5689797B2 (it)
CN (1) CN102170864B (it)
AU (1) AU2009279077C1 (it)
BR (1) BRPI0917567A2 (it)
CA (1) CA2733440C (it)
CY (1) CY1113744T1 (it)
DK (1) DK2222272T3 (it)
EA (1) EA019339B1 (it)
ES (1) ES2399179T3 (it)
GB (1) GB2465897B (it)
HR (1) HRP20130052T1 (it)
IL (1) IL210959A0 (it)
MX (1) MX2011001418A (it)
NZ (1) NZ590774A (it)
PL (1) PL2222272T3 (it)
PT (1) PT2222272E (it)
SI (1) SI2222272T1 (it)
SM (1) SMT201300007B (it)
WO (1) WO2010015818A1 (it)
ZA (1) ZA201100750B (it)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1976828T (lt) 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
GB0913672D0 (en) 2009-08-05 2009-09-16 Argenta Discovery Ltd Glitazones
KR20120107493A (ko) 2009-12-15 2012-10-02 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온염
GB2477540A (en) * 2010-02-05 2011-08-10 Argenta Therapeutics Ltd Respiratory disease treatment
WO2011098746A1 (en) * 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) * 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB2477743A (en) * 2010-02-10 2011-08-17 Argenta Therapeutics Ltd Enantiomers of 5-methyl-thiazolidine-2,4-dione glitazone compounds
GB201002243D0 (en) * 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
WO2014152843A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
CA2906035A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
EP3094328B1 (en) 2014-01-15 2020-08-19 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
CN107249621A (zh) * 2014-09-08 2017-10-13 哥谭生物制药股份有限公司 用于治疗肺结节病的粘液溶解剂
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2017176812A1 (en) 2016-04-05 2017-10-12 Immune Sensor, Llc cGAS ANTAGONIST COMPOUNDS
KR101841589B1 (ko) * 2016-12-02 2018-03-23 주식회사 종근당 로베글리타존을 유효성분으로 포함하는 섬유증 예방 또는 치료용 약학적 조성물
WO2019213611A1 (en) 2018-05-04 2019-11-07 Cirius Therapeutics, Inc. Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
ES3014615T3 (en) 2018-05-31 2025-04-23 Celltaxis Llc Method of reducing pulmonary exacerbations in respiratory disease patients
CA3129405A1 (en) 2019-02-08 2020-08-13 United States Government As Represented By The Department Of Veterans Affairs Growth hormone-releasing hormone antagonists and uses thereof
CN114126653B (zh) * 2019-07-18 2024-02-20 迈阿密大学 用于治疗结节病的方法的ghrh拮抗剂
US20210315937A1 (en) * 2020-04-08 2021-10-14 University Of South Florida Methods of treating inflammation
WO2021212054A1 (en) * 2020-04-17 2021-10-21 Cirius Therapeutics, Inc. Methods and compositions for treating subjects with metabolic disorders and coronavirus infections
US20230172921A1 (en) * 2020-04-30 2023-06-08 Minoryx Therapeutics S.L. Leriglitazone for treating lung inflammation and interstitial lung disease
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US12440488B2 (en) * 2020-12-01 2025-10-14 Reverspah Llc Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2335597A (en) * 1998-03-27 1999-09-29 Glaxo Group Ltd Stereoisomers of Troglitazone in the Treatment of Diabetes
US6127394A (en) * 1999-03-08 2000-10-03 The University Of Mississippi 1,2-Dithiolane derivatives
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
AU2001288271A1 (en) * 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
JP2005513031A (ja) * 2001-11-26 2005-05-12 アラクノーバ・セラピューティックス・リミテッド 肺線維症の処置のためのｐｐａｒアクチベーターの使用
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
EP1555021A1 (en) * 2004-01-16 2005-07-20 National Health Research Institutes Combinations of a mevalonate pathway inhibitor and a PPAR-gamma agonist for treating cancer
TW200745099A (en) * 2006-03-02 2007-12-16 Sankyo Co Optically active thiazolidinedione derivatives

Also Published As

Publication number Publication date
HRP20130052T1 (hr) 2013-02-28
EA019339B1 (ru) 2014-02-28
PL2222272T3 (pl) 2013-04-30
AU2009279077C1 (en) 2014-12-04
BRPI0917567A2 (pt) 2015-11-17
CA2733440A1 (en) 2010-02-11
EA201100305A1 (ru) 2011-10-31
ZA201100750B (en) 2012-06-27
IL210959A0 (en) 2011-04-28
NZ590774A (en) 2012-09-28
ES2399179T3 (es) 2013-03-26
GB2465897A (en) 2010-06-09
GB2465897B (en) 2011-02-09
HK1156501A1 (en) 2012-06-15
CN102170864B (zh) 2015-04-01
CA2733440C (en) 2016-06-28
JP2011529953A (ja) 2011-12-15
CN102170864A (zh) 2011-08-31
CY1113744T1 (el) 2016-06-22
PT2222272E (pt) 2013-01-29
DK2222272T3 (da) 2013-02-11
AU2009279077A1 (en) 2010-02-11
GB201000468D0 (en) 2010-02-24
AU2009279077B2 (en) 2014-07-03
SI2222272T1 (sl) 2013-03-29
MX2011001418A (es) 2011-07-20
EP2222272A1 (en) 2010-09-01
JP5689797B2 (ja) 2015-03-25
EP2222272B1 (en) 2012-11-07
WO2010015818A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
SMT201300007B (it) Trattamento di una malattia respiratoria
NL301305I2 (nl) Vibegron of een farmaceutisch aanvaardbaar zout daarvan
NL301166I2 (nl) Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301071I2 (nl) alpelisib of een farmaceutisch aanvaardbaar zout ervan
IL246697B (en) Multiple exon skipping compositions for use in treating muscular dystrophy
PL2257305T3 (pl) Nowy farmaceutyczny preparat do leczenia stanu przedrzucawkowego
EP2296593A4 (en) MEDICAL HEAD COVER
EP2341974A4 (en) CATHETER ARRANGEMENT
BRPI0906366A2 (pt) Inalador
BRPI0914817A2 (pt) inalador
DK2330887T3 (da) Behandlingsindretning
HRP20181767T1 (hr) Postupak proizvodnje zubarskog pribora
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
PL2435825T3 (pl) Sposoby leczenia chorób
BRPI0906779A2 (pt) Inalador
DK2173831T3 (da) Brøndbehandling
EP2052757A4 (en) MEDICAL CAPSULE
SMT201400053B (it) Forme farmaceutiche orali di bendamustina
FI20085693A0 (fi) Biosignaalin prosessointi
EP3381471C0 (en) PAIN TREATMENT
BRPI0906367A2 (pt) inalador
HRP20160577T1 (hr) Liječenje osteoartritisa
FI20096402A0 (fi) Veriryhmästatuksen käyttö II
BRPI0906369A2 (pt) Inalador
PT3133396T (pt) Métodos de tratamento utilizando fármacos eliminadores de amoníaco